SeaX Ventures Eyes Philippine Market for US Drug Trials

Dr. Supachai "Kid" Parchariyanon, founder of SeaX Ventures, is advocating for the Philippines as a viable location for conducting US drug trials. During a recent visit to Manila, he shared insights on the potential benefits of utilizing the country's healthcare system to facilitate clinical trials for innovative treatments.

Parchariyanon, who also runs a deep-tech investment fund based in Bangkok and the US, emphasized the urgency of providing timely access to medical advancements, citing a personal story about a billionaire friend whose wife was successfully treated for pancreatic cancer in the US after being given only months to live by top hospitals in Thailand. This narrative underscores the importance of timely intervention in healthcare.

In partnership with RISE, SeaX Ventures launched the Southeast Asia Health Innovation Hub in Bangkok, which aims to reach 100 million patients across the region. The hub currently connects with 30 million patients through 50 health systems in Thailand, with ambitions to expand its reach significantly. Parchariyanon noted that the hub's success in Thailand could be replicated in the Philippines, where he estimates there are close to 1,300 hospitals and a population of about 115 million.

While clinical trials are not new to the Philippines, Parchariyanon pointed out that many existing trials are investigator-initiated, often lacking the commercial backing of pharmaceutical companies. He believes that the Philippines could become a more attractive destination for trials intended to register and sell new drugs, especially given the lower costs associated with conducting trials in the country, which he stated are significantly less than US costs.

However, he cautioned that discussions with hospitals in the Philippines are still in the preliminary stages, with no formal agreements yet in place. He mentioned that the hub's launch announcement lists the Philippines among countries under consideration for onboarding, with expectations for acceleration in discussions in the latter half of the year.

In terms of patient recruitment, Parchariyanon noted that while US hospitals often present multiple trial options to patients, the Philippines remains a greenfield for clinical trials, with fewer trials competing for the same patients. He highlighted the potential for patients who have exhausted other treatment options to access costly new therapies through participation in trials, which could significantly alleviate financial burdens.

Regarding data ownership and patient rights, Parchariyanon stated that while the results of trials would be sent back to the US, patients would retain ownership of their own data. He acknowledged the need for clarity on how these arrangements align with the Philippines' Data Privacy Act, an important consideration as the country navigates the complexities of international clinical research.

As SeaX Ventures continues to explore opportunities in the Philippines, the firm aims to foster partnerships with local hospitals and healthcare providers to facilitate the introduction of new treatments.